Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies involved in the development of oral SERDs for breast cancer treatment. Core Insights - The report highlights the recent FDA approval of Imlunestrant, an oral SERD developed by Eli Lilly, for the treatment of ER+/HER2–/ESR1 mutant advanced or metastatic breast cancer, marking it as the second oral SERD approved after Elacestrant [18][19] - The EMBER-3 trial results indicate that Imlunestrant significantly improves progression-free survival (PFS) compared to standard endocrine therapy, with a median PFS of 5.5 months versus 3.8 months for standard therapy [23] - Giredestrant, developed by Roche, has shown positive results in the III phase evERA trial, demonstrating significant benefits in PFS compared to standard treatment in patients previously treated with CDK4/6 inhibitors [27] - Camizestrant, another oral SERD from AstraZeneca, has shown promising efficacy in the SERENA-6 trial, with a median PFS of 16.6 months when combined with CDK4/6 inhibitors [33] Summary by Sections Section 1: Focus on Innovative Drugs - The report reviews the advancements in innovative drugs, particularly in the field of breast cancer treatment, emphasizing the importance of oral SERDs [2][5] Section 2: Current Status of ER+ Breast Cancer Therapies - The report discusses the current landscape of therapies for ER+ breast cancer, including the mechanisms of action for various anti-estrogen therapies and the challenges of resistance faced by patients [10][8] Section 3: Clinical Development of New Oral SERDs - The report details the clinical development progress of several new oral SERDs, including Imlunestrant, Giredestrant, and Camizestrant, highlighting their respective phases and trial outcomes [12][11][33] Section 4: Market Dynamics and Company Performance - The report provides insights into the market dynamics of the biotech sector, including stock performance of key companies involved in the development of innovative cancer therapies [46][49]

Investment Rating - The report maintains an investment rating of "Outperform" with a target of A [7] Core Insights - The report highlights the positive results from Takeda's new generation oral TYK2 inhibitor, zasocitinib (TAK-279), for treating moderate to severe plaque psoriasis, with over 50% of participants achieving skin clearance or nearly clear skin (PASI 90) at week 16, and about 30% achieving complete clearance (PASI 100) [3][4] - The report suggests that there are multiple catalysts expected in the sector, including academic conferences and data readouts, which could provide investment opportunities [2] - The report emphasizes the potential of other TYK2 inhibitors, particularly Eifang Biopharma's D-2570, which has shown promising phase 2 clinical data [4][22] Summary by Sections Weekly New Drug Market Review - From December 15 to December 21, 2025, the top five gainers in the new drug sector were: Yahu Medicine (+12.03%), Cloudtop New Medicine (+9.32%), Aidi Pharmaceutical (+9.06%), Shiyao Group (+7.05%), and Ailis (+3.94%). The top five losers were: Chuangsheng Group (-16.03%), Beihai Kangcheng (-12.33%), Kedi (-11.88%), WuXi AppTec (-11.15%), and Nuocheng Jianhua (-10.99%) [1][17] Weekly Focus on Recommended Stocks - The report recommends focusing on companies with high certainty for overseas expansion, such as Sanofi Biopharma, Lianbang Pharmaceutical, and Kelun Biotech. It also highlights companies with potential overseas data catalysts, including Betta Pharmaceuticals, Hutchison China MediTech, and Ying'en Biopharma [2][21] Weekly New Drug Industry Analysis - Takeda's phase 3 clinical trials for zasocitinib have shown consistent results with previous phase 2 trials, indicating strong data reliability. The report also notes the potential for TYK2 inhibitors in treating Crohn's disease and ulcerative colitis [3][4][22] Weekly New Drug Application Approval & Acceptance - No new drug or new indication applications were approved domestically this week, but 11 new drug or new indication applications were accepted [5][26] Weekly New Drug Clinical Application Approval & Acceptance - This week, 55 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [11][28]

本次授予为一次性授予，无预留权益。激励计划涉及的激励对象共计179人，授予价格为16.87元/股。 12月19日，益方生物(688382.SH)披露2025年限制性股票激励计划(草案)，拟授予激励对象的限制性股票 数量为557.7万股，约占激励计划草案公布日公司股本总额的0.96%。 ...

（编辑 姚尧） 证券日报网讯 12月19日晚间，益方生物发布公告称，公司第二届董事会2025年第九次会议审议通过 《关于提请股东会授权董事会办理公司2025年限制性股票激励计划相关事宜的议案》等多项议案。 ...

益方生物(688382.SH)披露2025年限制性股票激励计划(草案)，拟授予激励对象的限制性股票数量为 557.7万股，约占激励计划草案公布日公司股本总额的0.96%。本次授予为一次性授予，无预留权益。激 励计划涉及的激励对象共计179人，授予价格为16.87元/股。 ...

智通财经APP讯，益方生物(688382.SH)披露2025年限制性股票激励计划(草案)，拟授予激励对象的限制 性股票数量为557.7万股，约占激励计划草案公布日公司股本总额的0.96%。本次授予为一次性授予，无 预留权益。激励计划涉及的激励对象共计179人，授予价格为16.87元/股。 ...

格隆汇12月19日丨益方生物(688382.SH)公布2025年限制性股票激励计划，本激励计划拟授予激励对象 的限制性股票数量为557.7000万股，约占本激励计划草案公布日公司股本总额57,834.8491万股的 0.96%。本次授予为一次性授予，无预留权益。本激励计划限制性股票的授予价格为16.87元/股。 ...

每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ 截至发稿，益方生物市值为171亿元。 每经AI快讯，益方生物（SH 688382，收盘价：29.5元）12月19日晚间发布公告称，本激励计划涉及的 激励对象共计179人，拟授出权益涉及的标的股票来源及种类本激励计划涉及的标的股票来源为公司向 激励对象定向发行的本公司人民币A股普通股股票；拟授予激励对象的限制性股票数量为557.7万股，约 占本激励计划草案公布日公司股本总额约5.78亿股的0.96%；限制性股票的授予价格为每股16.87元，即 满足授予条件和归属条件后，激励对象可以每股16.87元的价格购买公司股票，的有效期为自限制性股 票授予日起至激励对象获授的限制性股票全部归属或作废失效之日止，最长不超过60个月。 2024年1至12月份，益方生物的营业收入构成为：医药制造业占比100.0%。 （记者 曾健辉） ...

每经AI快讯，益方生物（SH 688382，收盘价：29.5元）12月19日晚间发布公告称，公司第二届2025年 第九次董事会会议于2025年12月19日以现场结合通讯形式召开。会议审议了《关于提请召开2026年第一 次临时股东会的议案》等文件。 2024年1至12月份，益方生物的营业收入构成为：医药制造业占比100.0%。 截至发稿，益方生物市值为171亿元。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 曾健辉） ...

2025 年限制性股票激励计划激励对象名单 益方生物科技（上海）股份有限公司 注：1、公司全部在有效期内的股权激励计划所涉及的标的股票总数累计未超过公司股本总 额的 20.00%。上述任何一名激励对象通过全部在有效期内的股权激励计划获授的公司股票 数量累计未超过公司股本总额的 1.00%。 2、本激励计划激励对象不包括独立董事、单独或合计持有公司 5%以上股份的股东或实际 控制人及其配偶、父母、子女。 益方生物科技（上海）股份有限公司董事会 2025 年 12 月 19 日 一、2025 年限制性股票激励计划（以下简称"本激励计划"）的分配情况 姓名 国籍 职务 获授的限制 性股票数量 （万股） 占本激励计 划拟授出全 部权益数量 的比例 占本激励计 划草案公布 日股本总额 的比例 一、董事、高级管理人员、核心技术人员 / / / / / / 二、骨干人员（共 179 人） 557.7000 100.00% 0.96% 合计 557.7000 100.00% 0.96% ...